ImmunoGen, Inc.
IMGN
주식 순위
#2903
ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes... ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes in the creation of antibody-drug conjugate (ADC) therapies for cancer treatment. A prominent drug in their pipeline is mirvetuximab soravtansine, an ADC designed to target folate-receptor alpha (FRa), which is currently undergoing Phase III clinical trials for patients with platinum-resistant ovarian cancer. Another significant candidate, Pivekimab sunirine, a CD123-targeting ADC, is progressing through Phase II studies for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Beyond its clinical efforts, the company's preclinical portfolio includes IMGC936, an ADC being co-developed with MacroGenics, Inc., and IMGN151, another anti-FRa therapeutic. ImmunoGen maintains strategic collaborations with a range of key industry players, such as Roche, Amgen/Oxford BioTherapeutics, Bayer HealthCare AG, Eli Lilly and Company, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Fusion Pharmaceuticals Inc., Debiopharm International SA, and MacroGenics, Inc. Founded in 1980, ImmunoGen, Inc. is headquartered in Waltham, Massachusetts.
주가
$31.23
마지막 동기화: 2024-02-13
시가총액
$6.24B
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 ImmunoGen, Inc. (IMGN)
카테고리
Healthcare
ImmunoGen, Inc. (IMGN)의 수익
2026 기준 수익 TTM: 0
ImmunoGen, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 수익 0과 동일입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
ImmunoGen, Inc.의 수익 기록 (2002 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2022 | $-221.71M | 59.16% |
| 2021 | $-139.30M | 213.94% |
| 2020 | $-44.37M | -57.39% |
| 2019 | $-104.13M | -37.97% |
| 2018 | $-167.87M | 74.85% |
| 2017 | $-96.01M | -38.74% |
| 2016 | $-156.73M | 158.04% |
| 2015 | $-60.74M | -14.89% |
| 2014 | $-71.36M | -1.99% |
| 2013 | $-72.81M | -0.69% |
| 2012 | $-73.32M | 25.82% |
| 2011 | $-58.27M | 13.87% |
| 2010 | $-51.18M | 59.74% |
| 2009 | $-32.04M | 0.14% |
| 2008 | $-31.99M | 68.80% |
| 2007 | $-18.95M | 6.38% |
| 2006 | $-17.82M | 63.13% |
| 2005 | $-10.92M | 86.01% |
| 2004 | $-5.87M | -70.56% |
| 2003 | $-19.95M | 37.55% |
| 2002 | $-14.50M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| $3.01B | - |
BE
|
